
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : VK2735
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Viking Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
CordenPharma, Viking Sign GLP-1 Supply Partnership for Peptides & Injectables
Details : CordenPharma provides fill-finish for the drug candidate's subcutaneous formulation and oral solid dosage manufacturing of VK2735. It is being evaluated for obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
March 11, 2025
Lead Product(s) : VK2735
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Viking Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Revolo Biotherapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : CordenPharma will Provide manufacturing support for Revolo Bio’s first-in-class peptide and immune system resetting drug product, ‘1104, for its upcoming Phase 2 clinical trials in patients with eosinophilic esophagitis (EoE) and allergic disease.
Product Name : ‘1104
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
April 15, 2021
Lead Product(s) : IRL201104
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Revolo Biotherapeutics
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : TAK-919
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Moderna Extends Lipid Supply For Coronavirus Vaccine
Details : The amended agreement now includes CordenPharma Chenôve (FR) and CordenPharma Colorado (US) for the manufacture of larger-scale volumes of lipids, while continuing to draw upon CordenPharma Switzerland’s long-standing reputation as a leader in special...
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
May 28, 2020
Lead Product(s) : TAK-919
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
